Doxil® - The first FDA-approved nano-drug: From an idea to a product

Handbook of Harnessing Biomaterials in Nanomedicine

Volumn , Issue , 2012, Pages 335-398

  Barenholz, Yechezkel Chezy ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84861694913     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4032/9789814364270     Document Type: Chapter

References (144)

1. Abuchowski, A., McCoy, J.R., Palczuk, N.C., van Es, T., and Davis, F.F., Efect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase, J. Biol. Chem. 252(11), 3582- 3586 (1977).
2. Allen, T.M., Liposomes with enhanced circulation time, U.S. Patent 4,837,028 (1989).
3. Allen, T.M., From fusion to magic bullets: the influence of Dimitri Papahdjopoulos, J. Liposome Res. 5, 657-667 (1995).
4. Allen, T.M., and Chon, A, Large unilamellar liposomes with low uptake by reticuloendothelial system. FEBS Lett. 223, 42-46 (1987).
5. Amselem, S., Cohen, R., Druckmann, S., Gabizon, A., Goren, D., Abra, R.M., Huang, A., New, R. and Barenholz, Y., Preparation and characterization of liposomal doxorubicin for human use. J. Liposome Res. 2, 93-123 (1992).
6. Amselem, S., Cohen, R. and Barenholz, Y., 1993a. In vitro tests to predict in vivo performance of liposomal dosage forms. Chem. Phys. Lipids 64, 219-237 (1993a).
7. Amselem, S., Gabizon, A. and Barenholz, Y, Evaluation of a new extrusion device for the production of stable oligolamellar liposomes in a liter scale. J. Liposome Res. 1, 287-301 (1989-90).
8. Amselem, S., Gabizon, A, and Barenholz, Y., Optimization and upscaling of doxorubicin-containing liposomes for clinical use. J. Pharm. Sci. 79, 1045-1052 (1990).
9. Amselem, S., Gabizon, A., and Barenholz, Y, A large-scale method for the preparation of sterile and nonpyrogenic liposomal formulations of defined size distributions for clinical use, in Liposome Technology, 2nd Edition, Vol. I, Liposome Preparation and Related Techniques (Gregoriadis, G., ed.), CRC Press, Boca Raton, FL, pp. 501-525 (1993b).
10. Andrews, P.A., Brenner, D.E., Chou, F.T., Kubo, H., Bachur, N.R, Facile and definitive determination of human Adriamycin and Daunorubicin metabolites by high-pressure liquid chromatography, Drug Metab. Dispos., 8, 152-156 (1980).
11. Avnir, Y, Ulmansky, R, Wasserman, V., Even-Chen, S., Broyer, M., Barenholz, Y., and Naparstek, Y, Amphipathic weak acid glucocorticoid prodrugs remote loaded into nano sterically stabilized liposomes: a novel approach to treat autoimmune arthritis. Arthritis Rheum., 58(1), 119-129 (2008).
12. Bandak, S., Ramu, A, Barenholz, Y, and Gabizon A., Reduced UV-induced degradation of doxorubicin encapsulated in polyethylene glycol-coated liposomes, Pharm. Res. 16, 841-846 (1999).
13. Bangham, A.D., Liposomes: the Babraham connection, Chem. Phys. Lipids 64, 275-285 (1993).
14. Barenholz, Y, Liposome production: Historic aspects. In: Liposome Dermatics (Braun-Falco, O., Korting, H.C., and Maibach, H.I., eds.), Springer Verlag, Berlin, pp. 69-81 (1992).
15. Barenholz, Y, Design of liposome-based drug carriers: from basic research to application as approved drugs. In: Medical Applications of Liposomes. (Lasic, D.D., and Papahadjopoulos, D. eds.) Elsevier Science, Amsterdam, 541-565 (1998).
16. Barenholz, Y, Liposome application: problems and prospects. Curr. Opin. Colloid Interface Sci. 6, 66-77 (2001).
17. Barenholz, Y, Relevancy of drug loading to liposomal formulation therapeutic efficacy, J. Liposome Res, 13, 1-8 (2003).
18. Barenholz, Y Amphipathic weak base loading into preformed liposomes having a transmembrane ammonium ion gradient: from the bench to approved Doxil. In: Liposome Technology, 3rd Edition, Gregoriadis, G., ed., Vol. II, Informa Healthcare, New York, pp. 1-26 (2007).
19. Barenholz, Y, and Amselem, S., Quality control assays in the development and clinical use of liposome-based formulations. In: Liposome Technology, 2nd Edition, Vol. I, Liposome Preparation and Related Techniques. (Gregoriadis, G., ed.), CRC Press, Boca Raton, FL, pp. 527-616 (1993b).
20. Barenholz, Y, Amselem, S., Goren, D., Cohen, R, Gelvan, D., Samuni, A., Golden, E.B., and Gabizon, A, Stability of liposomal-doxorubicin formulation: problems and prospects. Med. Res. Rev. 13, 449-491 (1993a).
21. Barenholz, Y, and Crommelin, D.J.A, Liposomes as pharmaceutical dosage forms. In: Encyclopedia of Pharmaceutical Technology. (Swarbrick, J., and Boylan, J.C., eds.), Vol. 9, Marcel Dekker, New York, pp. 1-39 (1994).
22. Barenholz, Y, and Cohen, R, Rational design of amphiphile-based drug carriers and sterically stabilized carriers, J. Liposome Res., 5, 905-932 (1995).
23. Barenholz, Y, Druckmann, N.S., Cohen, R, Amselem, S., Sulkes, A, and Gabizon, A, Complete pharmacokinetic analysis of liposome-associated doxorubicin in cancer patients. In: Recent Advances in Chemotherapy: Antimicrobial Section 1: Proceedings of the 16th Int'l Congress of Chemotherapy, (Rubinstein, E., and Adam, D., eds), E. Lewin-Epstein Ltd. p. 303.1 (Jerusalem, 1989).
24. Barenholz, Y, and Gabizon, A, Liposome/doxorubicin composition and method, U.S. Patent 4,898,735 (February 6, 1990).
25. Barenholz, Y, and Gabizon, A, Liposome/anthraquinone drug composition and method, U.S. Patent 5,043,166 (August 27, 1991) (also see US Patent 4,797,285).
26. Barenholz, Y, and Haran, G., Method of amphipathic drug loading in liposomes by pH gradient, U.S. Patent 5,192,549 (March 9, 1993).
27. Barenholz, Y, and Haran, G., Liposomes: efficient loading and controlled release of amphipathic molecules, U.S. Patent 5,316,771 (May 31, 1994) (also Europe and Israel).
28. Barenholz, Y, Naparstek, Y, Avnir, Y, and Ulmansky, R, The use of liposomal glucocorticoids for treating inflammatory states, U.S. Patent 7,744,920, 2010, (June 29, 2010).
29. Bassermann, R, Changes of vascular pattern of tumors and surrounding tissue during diferent phases of metastatic growth, Recent Results Cancer Res., 100, 256-257 (1986).
30. Beijnen, J.H., Rosing, H., de Vries, P.A., and Underberg, W.J.M., Stability of anthracycline antitumor agents in infusion fluids, J. Parenter. Sci. Technol., 39, 220-222 (1985).
31. Belchetz, P. E., Crawley, J. C, Braidman, I. P., and Gregoriadis, G., Treatment of Gauchers disease with liposome-entrapped glucocerebroside: beta-glucosidase. Lancet 8029, 116-117 (1977).
32. Blum, R.H., Carter, S.K., Adriamycin: a new anticancer drug with significant clinical activity. Ann. Intern. Med., 1974, 80, 249-259.
33. Blume, G., and Cevc, G., Liposomes for sustained drug release in vivo, Biochim. Biophys. Acta 1029, 91-97 (1990).
34. Bolotin, E.M., Cohen, R., Bar, L.K., Emanuel, N., Ninio, S., Lasic, D.D. and Barenholz, Y, Ammonium sulfate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandoliposomes, J. Liposome Res. 4, 455-479 (1994).
35. Cabanes, A., Even-Chen, S., Zimberof, J., Barenholz, Y., Kedar, E., and Gabizon, A., Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2. Clin. Cancer Res. 5, 687-693 (1999).
36. Clerc, S., and Barenholz, Y, A quantitative model for using acridine orange as a trans-membrane pH gradient probe, Anal. Biochem., 259, 104-111 (1998).
37. Diop-Frimpong, B., Chauhan, V.P., Krane, S., Boucher, Y, and Jain, R.K., Losartan inhibits collagen I synthesis and improves distribution and efficacy on nanotherapeutics in tumors. PNAS, on line (2011).
38. Druckmann, S., Gabizon, A., and Barenholz, Y, Separation of liposome-associated doxorubicin from non-liposome-associated doxorubicin in human plasma: implications for pharmacokinetic studies, Biochim. Biophys. Acta 980, 381-384 (1989).
39. Emanuel, N., Kedar, E., Bolotin, E.M., Smorodinsky, N.I., and Barenholz, Y, Preparation and characterization of doxorubicin-loaded sterically stabilized immunoliposomes, Pharm. Res. 13, 352-359 (1996a).
40. Emanuel, N., Kedar, E., Bolotin, E.M., Smorodinsky, N.I. and Barenholz, Y., Targeted delivery of doxorubicin via sterically stabilized immunoliposomes: pharmacokinetics and biodistribution in tumor-bearing mice, Pharm. Res. 13, 861-868 (1996b).
41. Even-Or (Flasterstein), O., Samira, S., Rochlin, E., Balasingam, S., Mann, A.J., Lambkin-Williams, R, Spira, J., Goldwaser, I., Ellis, R., and Barenholz, Y., Immunogenecity protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine, Vaccine, 28, 6527-6541 (2010).
42. Forssen, E.A, and Tokes, Z.A In vitro and in vivo studies with adriamycin liposomes, Biochem. Biophys. Res. Commun., 91, 1295-1301 (1979).
43. Forssen, E.A., and Tokes, Z.A., Use of anionic liposomes for the reduction of chronic doxorubicin induced cardiotoxicity Proc. Natl. Acad. Sci. USA, 78, 1873-1877 (1981).
44. Forssen, E.A., and Tokes, Z.A., Improved therapeutic benefits of doxorubicin by entrapment in anionic liposomes, Cancer Res., 43, 546-550 (1983).
45. Gabizon, A., Amselem, S., Goren, D., Cohen, R, Druckmann, S., Fromer, I. Chisin, R. Peretz, T, Sulkes, A, and Barenholz, Y, Preclinical and clinical experience with doxorubicin with a doxorubicin liposome preparation, J. Liposome Res. 1, 491-502 (1991b).
46. Gabizon, A.A., and Barenholz, Y., Adriamycin-containing liposomes in cancer chemotherapy. In: Liposomes as Drug Carriers (Gregoriadis, G., ed.) Wiley, New York, pp. 365-379 (1988).
47. Gabizon, A., and Barenholz, Y, Liposomal anthracyclines - from basics to clinical approval of pegylated liposomal doxorubicin. In: Liposomes: Rational Design (Janof, AS., ed.), Marcel Dekker, New York, pp. 343-362 (1999).
48. Gabizon, A, and Barenholz, Y, A method for drug loading, WO 2005/046643 A2 (2005).
49. Gabizon, A.A., Barenholz, Y, and Bialer, M., Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs, Pharm. Res., 10, 703-708 (1993).
50. Gabizon, A, Catane, R, Uziely, B., Kaufman, B., Safra, T, Cohen, R, Martin, F., Huang, A, and Barenholz, Y, Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes, Cancer Res, 54, 987-992 (1994).
51. Gabizon, A., Chisin, R Amselem, S., Druckmann, S., Cohen, R, Goren, D., Fromer, I., Peretz, T, Sulkes, A, and Barenholz, Y, Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated Adriamycin, Br. J. Cancer, 64, 1125-1132 (1991a).
52. Gabizon, A, Dagan, A., Goren, D., Barenholz, Y, and Fuks, Z., Liposomes as in vivo carriers of Adriamycin: reduced cardiac uptake and preserved antitumor activity, Cancer Res. 42, 4734-4739 (1982).
53. Gabizon, A, Goren, D., and Barenholz, Y, Investigation on the anti-tumor efficacy of liposome associated doxorubicin in murine tumor models, Isr. J. Med. Sci. 24, 512-517 (1988).
54. Gabizon, A, Goren, D., Fuks, Z., Barenholz, Y, Dagan, A. and Meshorer, A., Enhancement of Adriamycin delivery to liver metastatic cells with increased tumoricidal efect using liposomes as drug carriers, Cancer Res. 43, 4730-4735 (1983).
55. Gabizon, A., Goren, D., Fuks, Z., Meshorer, A., and Barenholz, Y, Superior therapeutic activity liposome-associated Adriamycin in a murine metastatic tumour model, Br. J. Cancer 51, 681-689 (1985).
56. Gabizon, A., Goren, D., Ramu, A., and Barenholz, Y., Design, characterization and anti-tumor activity of Adriamycin-containing phospholipid vesicles. In: Targeting of Drugs with Synthetic Systems (Gregoriadis, G., Senior, J. and Poste, G., eds.), NATO ASI Series, Plenum, New York, pp. 229-238 (1986a).
57. Gabizon, A, Huang A, Martin, F., and Barenholz. Y, Doxorubicin encapsulation in polyethylene glycol-coated liposomes: initial clinical pharmacokinetic studies in solid tumors. In: Stealth Liposomes (Lasic, D.D., and Martin F., eds), CRC Press, Boca Raton, FL, Chapter 21, pp. 245-255 (1995).
58. Gabizon, A, Meshorer, A, and Barenholz, Y, Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration, J. Natl. Cancer Inst. 77, 459-469 (1986b).
59. Gabizon, A, and Papahadjoupoulos, D., Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors, Proc. Natl. Acad. Sci. USA, 85, 6949-6953 (1988).
60. Gabizon, A, Peretz, T, Sulkes, A., Amselem, S., Ben-Yosef, R, Ben-Baruch, N., Catane, R, Biran, S., and Barenholz, Y, Systemic administration of doxorubicin-containing liposomes in cancer patients: phase I study, Eur. J. Cancer Clin. Oncol., 25, 1795-1803 (1989a).
61. Gabizon, A, Shmeeda, H., and Barenholz, Y, Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies, Clin. Pharmacokinet, 42, 419-436 (2003).
62. Gabizon, A.A., Sulkes, A, Peretz, T, Druckmann, S., Goren, D., Amselem, S., and Barenholz, Y, Liposome-associated doxorubicin: preclinical pharmacology and exploratory clinical phase. In: Liposomes in the Therapy of Infectious Diseases and Cancer (Fidler, I.J., and Lopez-Berestein, G., eds.) A.R.L., New York, pp. 391-402 (1989b).
63. Garbuzenko, O., Barenholz, Y, and Priev, A., Efect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer, Chem. Phys. Lipids, 135, 117-129 (2005).
64. Goormaghtigh, E., and Ruysschaert, J.M., Anthracycline glycoside membrane interaction, Biochim. Biophys. Acta, 779, 271-188 (1984).
65. Gordon, AN., Fleagle, J.T., Guthrie, D., Parkin, D.E., Gore, M.E., and Lacave, A.J., Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan, J. Clin. Oncol, 19(14), 3312-3322 (2001).
66. Gordon, AN., Granai, CO., Rose, P.G., Hainsworth, J., Lopez, A, Weissman, C, Rosales, R, Sharpington, T, Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer, J. Clin. Oncol, 18(17), 3093-3100 (2000).
67. Goren, D., Liposomes as doxorubicin carriers: a means to improve the therapeutic index of the drug, Ph.D. thesis submitted and approved by the Hebrew University of Jerusalem (1990).
68. Goren, D., Gabizon, A., and Barenholz, Y., The influence of physical characteristics of liposomes containing doxorubicin on their pharmacological behavior, Biochim. Biophys. Acta, 1029, 285-294 (1990).
69. Gabizon, A., Isacson, R., Rosengarten, O., Tzemach, D., Shmeeda, H., and Sapir, R., An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin, Cancer Chemother. Pharmacol., 1(4), 695-702 (2008).
70. Grant, G.J., Barenholz, Y., Bansinath, M., and Davidson, E.M. A novel liposomal Bupivacaine formulation to produce ultralong-acting analgesia, Anesthesiology, 101, 133-137 (2004).
71. Grant, G.J., Barenholz, Y., Piskoun, B., Bansinath, M., Turndorf, H., and Bolotin, E., DRV liposomal bupivacaine: preparation, characterization and in vivo evaluation in mice, Pharm. Res., 18, 336-343 (2001).
72. Gregoriadis, G., and Senior, J., Liposomes in vivo: a relationship between stability and clearance? In: Targeting of Drugs with Synthetic Systems (Gregoriadis, G., Senior, J., Poste, G., eds), London, Plenum, pp. 183-192 (1986).
73. Gregoriadis, G., Swain, C.P., Wills, E.J., and Tavill, A.S., Drug-carrier potential of liposomes in cancer chemotherapy, Lancet, 1, 1313-1316 (1974).
74. Gundersen, S., Kvinnsland, S., Klepp, O., Kvaloy, S., Lund, E., Host, H., Weekly Adriamycin versus VAC in advanced breast cancer. A randomized trial, Eur. J. Cancer Clin. Oncol., 22, 1431-1434 (1986).
75. Haran, G., Cohen, R., Bar, L.K., and Barenholz, Y., Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim. Biophys. Acta 1151, 201-215 (1993).
76. Hashizume, H., Baluk, P., Morikawa, S., McLean, J.W., Thurston, G., Roberge, S., Jain, R.K., and MacDonald, D.M., Openings between defective endothelial cells explain tumor vessel leakiness, Am. J. Pathol., 156, 1363-1380 (2000).
77. Horowitz, A.T., Barenholz, Y., and Gabizon, A.A., In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release, Biochim. Biophys. Acta, 1109, 203-209 (1992).
78. Hunt, C.A., and Papahadjopoulous, D.P., Method for producing liposomes in selected size range, US patent 4,529,561 (July 16, 1985).
79. Hwang, K.J., Liposome pharmacokinetics. In: Liposomes: From Biophysics to Therapeutics (Ostro, M.J., ed.), Marcel Dekker: New York, p. 109 (1987).
80. Joseph, A., Itskovitz Cooper, N., Samira, S., Flasterstein, O., Eliyahu, H., Simberg, D., Goldwaser, I., Barenholz, Y, and Kedar, E. A new intranasal influenza vaccine based on a novel polycationic lipid ceramide carbamoyl spermine (CCS). I. Immunogenicity and efficacy studies in mice, Vaccine, 24, 3990-4006 (2006).
81. Kedar, E., Braun, E., Rutkowski, Y, Emanuel, N. and Barenholz, Y, Delivery of cytokines by liposomes. II. Interleukin-2 encapsulated in long-circulating sterically stabilized liposomes: immunomodulatory and anti-tumor activity in mice. J. Immunother. 16, 115-124 (1994).
82. Kedar, E., Rutkowski, Y, Braun, E., Emanuel, N., and Barenholz, Y, Delivery of cytokines by liposomes. I. Preparation and characterization of interleukin-2 encapsulated in long-circulating sterically stabilized liposomes, J. Immunother, 16, 47-59 (1994).
83. Kenyon J, 2008. Chemotherapy and cardiac toxicity - the lesser of two evils, Doctors Lounge Website, available at http://www.doctorslounge.com/index.php/blogs/page/14030.
84. Klivanov, A.L., Maruyama, K., Torchilin, V.P., and Huang, L., Amphipathic polyethyleneglycols efectively prolong the circulation time of liposomes, FEBS Lett, 268, 235-237 (1990).
85. Kumai, K, Takahashi, T, Tsubouchi, K, Shino, K., Ishbiki, KK., and Abe, O., Selective hepatic arterial infusion of liposomes containing anti tumor agents. Jpn. J. Cancer Chemother, 12, 1946-1948 (1985).
86. Lasic, D.D., On the history of liposomes. In: Handbook of Non-Medical Applications of Liposomes (Lasic, D.D., and Barenholz Y, eds), Vol. 1, CRC Press, Boca Raton, FL, pp. 1-12 (1996).
87. Lasic, D.D., Valner, J.J., and Working, P.K, Sterically stabilized liposomes in cancer therapy and gene delivery, Curr. Opin. Mol. Ther, 1, 177-185 (1999).
88. Lasic, D.D., Ceh, B., Stuart, M.C.A., Guo, L., Frederik, P.M., and Barenholz, Y, Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery, Biochim. Biophys. Acta, 1239, 145-156 (1995).
89. Lasic, D.D, Frederik, P.M., Stuart, M.C.A., Barenholz, Y, and McIntosh, T.J., Gelation of liposome interior. A novel method for drug encapsulation, FEBS Lett, 312, 255-258 (1992).
90. Lasic, D.D., and Martin, F. (eds), Stealth Liposomes, CRC Press, Boca Raton, FL(1995).
91. Lichtenberg, D., and Barenholz, Y, Liposomes: Preparation, characterization, and preservation. In: Methods of Biochemical Analysis (Glick, D., ed.) Wiley, NY, 33, pp. 337-462 (1988).
92. Lopez-Berestein, G., Fainstein, V., Hopfer R, et al, Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study J. Infect. Dis, 151, 704-710 (1985).
93. Mace, K., Mayhew, E., Mihich, E., Ehrke, M.J., Alterations in murine host defense functions by Adriamycin or liposome-encapsulated Adriamycin. Cancer Res., 48, 130-136 (1988).
94. Maeda, H., Bharate, G.Y, and Daruwalla, J., Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-efect, Eur. J. Pharm. Biopharm., 71, 409-419, (2009).
95. Martin, F., Caignard, A, Olson, O., Jeanin, J.F., Leclerc, A., Tumoricidal efect of macrophages exposed to Adriamycin in vivo and in vitro, Cancer Res., 42, 3851-3855 (1982).
96. Matsumura, Y, and Maeda, H., A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumor tropic accumulation of proteins and antitumor agent SMANCS, Cancer Res. 46, 6387-6392 (1986).
97. Mayhew, E., and Rustum, Y, The use of liposomes as carriers of therapeutic agents. In: Molecular Basis of Cancer. Part B: Macromolecular Recognition, Chemotherapy and Immunology (Rein, R., ed.), Alan R Liss, New York, 301-310 (1985).
98. Mayhew, E., Rustum, Y, and Vail, W.J., Inhibition of liver metastases of M5076 tumor by liposome-entrapped Adriamycin, Cancer Drug Deliv, 1, 43-58 (1983).
99. Mayhew, E.G., Goldrosen, M.H., Vaage, J., and Rustum, Y.M., Efects of liposome-entrapped doxorubicin on liver metastases of mouse colon carcinomas 26 and 38 J. Natl. Cancer Inst, 78, 707-713 (1987).
100. McKelvey E.M., Gottlieb, J.A, Wilson H.E. et al., Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma, Cancer, 38, 1484-1493 (1976).
101. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., Gianni L, Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity,. Pharmacol. Rev. 56 (2), 185-229 (June 2004).
102. Needham, D., Anyarambhatia, G., Kong, G., and Dewhirst, M.W A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in human tumor xenograft model. Cancer Res., 60, 1197-1201 (2000).
103. Needham, D., and Dewhirst, M.W., The development and testing of new temperature-sensitive drug delivery system for treatment of solid tumors. Adv. Drug Deliv. Rev., 53, 285-305 (2001).
104. Olson, F., Mayhew, E., Maslow D., Rustum, Y., and Szoka, F, Characterization, toxicity, and therapeutic efficacy of Adriamycin encapsulated in liposomes. Eur. J. Cancer Clin. Oncol, 1982, 18, 167-176.
105. Perez-Soler, R., Lopex-Berestein, G., Kasi, L.P., et al, Distribution of technetium-99m labeled multilamellar liposomes in patients with Hodgkins disease, J. Nucl. Med, 26, 743-749 (1985).
106. Peng, X., Chen, B., Lim, C.C., Sawyer, D.B., The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine, Mol. Intervent. 5 (3): 163-171 (June 2005).
107. Peleg-Shulman, T., Gibson, D., Cohen, R., Abra, R., and Barenholz, Y., Characterization of sterically stabilized cisplatin liposomes by nuclear magnetic resonance, Biochim. Biophys. Acta, 1510, 278-291 (2001).
108. Poste, G., Liposome targeting in vivo: problems and opportunities, Biol. Cells, 47, 19-38 (1983).
109. Poste, G., Bucana, C., Raz, A., Bugelski, P., Kirsh, R., and Fidler, I.J., Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery, Cancer Res., 42, 1412-1422 (1982).
110. Rahman, A., Carmichael, D., Harris, M., and Roh, J.K., Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes, Cancer Res, 46, 2295-2299 (1986a).
111. Rahman, A., Fumagalli, A., Barbieri, B., Schein, P.S., and Casazza, A.M., Anti-tumor and toxicity evaluation of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes, Cancer Chemother. Pharmacol., 16, 22-27 (1986b).
112. Rahman, A., Kessler, A., More, N., et al., Liposomal protection of Adriamycin-induced cardiotoxicity in mice, Cancer Res, 40, 1532-1537 (1980).
113. Rahman, A, More, N., and Schein, P.S., Doxorubicin-induced chronic cardiotoxicity and its protection by liposomal administration, Cancer Res., 42, 1817-1822 (1982).
114. Rahman, A, Roh, J.K., and Treat, J., Preclinical and clinical pharmacology of doxorubicin entrapped in cardiolipin liposomes. In: Liposomes in the Therapy of Infectious Diseases and Cancer (Lopez-Berestein, G., and Fidler, I.J., eds.), Alan R Liss, New York, 367-389 (1989).
115. Rahman, A., White, G., More, N., Schein, P.S., Pharmacological, toxicological, and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes, Cancer Res., 45(2), 796-803 (February 1985).
116. Richardson, V.J., Ryman, B.E., Jewkes, R.F. et al, Tissue distribution and tumor localization of technetium-99M labeled liposomes in cancer patients. Br. J. Cancer, 40, 35-43 (1979).
117. Schroeder, A., Avnir Y., Weisman, S., Najajreh, Y., Gabizon, A., Talmon, Y, Kost, J., and Barenholz, Y, Controlling liposomal drug release with low frequency ultrasound: mechanism and feasibility, Langmuir, 23(7): 4019-4025 (2007).
118. Schroeder, A, Honen, R, Turjeman, K., Gabizon, A., Kost, J., and Barenholz, Y., Ultrasound triggered release of cisplatin from liposomes in murine tumors, J. Control. Release, 137, 63-68 (2009a).
119. Schroeder, A, Kost, J., and Barenholz, Y, Ultrasound, liposomes, and drug delivery: principles for using ultrasound to control the release of drugs from liposomes, Chem. Phys. Lipids, 162, 1-16 (2009b).
120. Sculier, J.P., Coune, A., Brassine, C, et al, Intravenous infusion of high doses of liposomes containing NSC 251635, a water-insoluble cytostatic agent. A pilot study with pharmacokinetic data, J. Clin. Oncol, 4, 789-797 (1986).
121. Sculier, J.P., Coune, A., Meunier, F., et al, Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections, Eur. J. Cancer Clin. Oncol., 24, 527-538 (1988).
122. Skeel, R.T., Handbook of Cancer Chemotherapy, 5th Edition, Lippincott Williams & Wilkins, Philadelphia, pp. 100-101 (1999).
123. Storm, G., Roerdink, F.H., Steerenberg, PA., de Jong, W.H., and Crommelin, D.J A., Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model. Cancer Res. 47, 3366-3372 (1987).
124. Stein, W.D., Transport and Diffusion Across Cell Membranes, Academic Press, Orlando, FL, Chapter 2 (1986).
125. Solomon, R, and Gabizon, A.A., Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal doxorubicin. Clin. Lymphoma Myeloma, 8, 21-32 (2008).
126. Symon, Z., Peyser, A, Tzemach, D., Lyass, O., Sucher, E., Shezen, E., and Gabizon, A, Selective delivery of doxorubicin to patients with breast carcinoma metastases by Stealth liposomes, Cancer, 86, 72-78 (1999).
127. Szebeni, J., and Barenholz, Y, Chapter 11, Complement Activation, Immunogenicity, and Immune Suppression as Potential Side Efects of Liposomes, This book (2011).
128. Szebeni, J., Alving, C.R, Rosivall, L., Bunger, R., Baranyi, L., Bedocs, P., Toth, M., and Barenholz, Y, Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles, J. Liposome Res. 17, 1-11 (2007).
129. Takimoto, C.H., Calvo, E., Principles of oncologic pharmacotherapy. In: Cancer Management: A Multidisciplinary Approach, 11th edition (Pazdur, R., Wagman, L.D., Camphausen, K.A., and Hoskins, W.J., eds.), UBM Medica, Norwalk, CT (2008).
130. Tirosh, O., Barenholz, Y., Katzhendler, Y, and Priev, A., Hydration of polyethylene glycol-grafted liposomes, Biophys. J., 74, 1371-1379 (1998).
131. Tirosh, O., Kohen, R, Katzhendler, J., Gorodetsky, R. and Barenholz, Y, Novel synthetic phospholipid protects lipid bilayers against oxidative damage: role of hydration layer and bound water, J. Chem. Soc, Perkin Trans. 2, 383-389 (1997).
132. Treat, J., Greenspan, A.R., Rahman, A., Liposome encapsulated doxorubicin -preliminary results of phase I and phase II trials. In: Liposomes in the Therapy of Infectious Diseases and Cancer (Lopez-Berestein, G., and Fidler, I.J., eds.), Alan R Liss, New York, pp. 353-365 (1989).
133. Van Hoesel, Q.G., Steerenberg, P.A., Crommelin, D.J., et al., Reduced cardiotoxicity and nephrotoxicity with preservation of antitumor activity of doxorubicin entrapped in stable liposomes in the LOU/M Wsl rat, Cancer Res, 44, 3698-3705 (1984).
134. Veronese, F.M., and Harris, J.M., Introduction and overview of peptide and protein pegylation, Adv. Drug Deliv. Rev., 54(4), 453-456 (2002).
135. Veronese, F. M. , and Pasut, G., Pegylation, successful approach to drug delivery, Drug Discov. Today, 10(21), 1451-1458 (2005).
136. Wasserman, V., Kizelsztein, P., Garbuzenko, O., Kohen, R, Ovadia, H., Tabakman, R., and BarenholzY., The antioxidant Tempamine: in vitro antitumor and neuroprotective efects and optimization of liposomal encapsulation and release, Langmuir, 23(4), 1937-1947 (2007).
137. Weiss, R.B., The anthracyclines: will we ever find a better doxorubicin? Semin. Oncol. 19(6), 670-686 (1992).
138. Woodle, M.C., Surface-modified liposomes: assessment and characterization for increased stability and prolonged blood circulation, Chem. Phys Lipids, 64, 249-262 (1993).
139. Woodle, M.C., and Lasic D.D., Sterically stabilized liposomes, Biochim. Biophys. Acta, 113, 171-199 (1992).
140. Woodle, M.C., Martin, F.J., Yau-Yang, A., Redmann, C.T., Liposomes with enhanced circulation time, U.S. Patent 5,013,556 (May 07, 1991).
141. Woodle, M.C., Newman, M., Collins, L., Redmann, C, and Martin, F., Improved long circulating (Stealth®) liposomes using synthetic lipids. Symp. Control. Release Bioact. Mater, 17, 77 (1990).
142. Zhang, Y.P., Ceh, B., and Lasic, D.D., Liposomes in Drug Delivery in Polymeric Biomaterials, 2nd edition (Damitziu, S., ed.), Marcel Dekker New York, Chapter 29, pp. 783-821 (2001).
143. Zucker, D., and Barenholz, Y., Optimization of Vincristine-Topotecan combination - paving the way for improved chemotherapy regimens by nanoliposomes, J. Control. Release, 146, 326-333 (2010).
144. Zucker, D., Marcus, D., Barenholz, Y, and Goldblum, A., Liposome drugs loading efficiency: a working model based on loading conditions and drugs physicochemical properties, J. Control. Release, 139, 73-80 (2009).